In-vitro assessment of CYP3A4 and CYPC29 inhibition potential of Lupeol using human liver microsomes

  • LAXMAN DATTU KHATAL Bharati Vidyapeeth College of Pharmacy, Kolhapur, Near Chitranagri, Kolhapur-416013, Maharashtra, India
  • Harinath More

Abstract

Background: Lupeol is a dietary triterpene, possesses numerous biological activities. Lupeol is currently under development for chemotherapy and chemoprevention. The aim of present study was to determine the potential inhibitory effect of Lupeol on cytochrome P450 (CYP3A4 and CYP2C9 isozymes) activities in human liver microsomes (HLM).


Methods:  The inhibition studies were conducted using testosterone 6β-hydroxylase (CYP3A4), and diclofenac 4’-Hydroxylase (CYP2C9) activity assay using positive control Ketoconazole and Sulphaphenazole, respectively. Inhibition study was performed by incubating lupeol (0 to 20 μM) with human liver microsomes, and the metabolite formation was analyzed by liquid chromatography-Tandem Mass Spectrometry (LC-MS/MS).


Results: Luepol did not inhibit CYP3A4 and CYP2C9 isozymes mediated activities in human liver microsomes up to a maximum tested concentration of 20µM based on solubility under tested invitro conditions.


Conclusions: Lupeol is not an inhibitor of the CYP3A4 and CYP2C9 isozymes. IC50 is greater than highest tested concentration as well as physiological concentration, where effect was measured with confidence. Therefore, clinically relevant pharmacokinetic herb-drug interactions are unlikely to occur between Lupeol and co-administered substrates of these CYP isozymes. Looking at the spectrum of biological activities and CYP inhibition potential of Lupeol; Lupeol can be used as adjuvant/ chemotherapy agent/ chemopreventive agent in therapy.


Keywords: Lupeol, HLM, CYP3A4 and CYP2C9, Inhibition, herb–drug interactions

Downloads

Download data is not yet available.

References

1. Margareth B. C. Gallo, Sarachine MJ, Biological Activities of Lupeol, International Journal of Biomedical and Pharmaceutical Sciences, 2009; 3 (Special Issue 1):46-66.
2. Siddique HR, Mishra SK, Karnes RJ, Saleem M, Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy, Clinical Cancer Research, 2011; 17(16): 5379–5391.
3. Saleem M, Lupeol, A Novel Anti-inflammatory and Anti-cancer Dietary Triterpene, Cancer Letter, 2009; 285(2):109–115.
4.0 Izzo AA, Ernst E, Interactions between herbal medicines and prescribed drugs: a systemic review, Drugs, 2001; 61:2163–75.
5. Wanwimolruk S, Phopin K, Prachayasittikul V , Cytochrome 450 Enzyme Mediated Herbal Drug Interactions (Part 2), EXCLI Journal, 2014; 13:869-896.
6. Haq I, Safety of medicinal plants, Pakistan Journal of Medical Research, 2004; 43:203–10.
7. Choi YH, Chin YW, Kim YG, Herb-drug interactions: focus on metabolic enzymes and transporters, Archives of Pharmacal Research, 2011; 34:1843–63.
8. Elvin-Lewis M, Should we be concerned about herbal remedies, Journal of Ethnopharmacology, 2001; 75:141–64.
9. Clarke SE, Jones BC, Human cytochrome P450 and their role in metabolism-based drug–drug interactions, in: A.D. Rodrigues (Ed.), Drug and Drug Interactions, seconded., Informa healthcare Inc., New York, 2008; 53–86.
10. Lin JH, Lu AY, Inhibition and induction of cytochrome P450 and the clinical implications, Clinical Pharmacokinetics, 1998; 35: 361–390.
11. Asha S, Vidyavathi M, Role of human liver microsomes in invitro metabolism of drugs, Applied Biochemistry and Biotechnology, 2010; 160: 1699–1722.
12. Zanger UM, Schwab M, Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacology & Therapeutics, 2013; 138:103–4.
13. Huang SM, Lesko LJ, Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?, The Journal of Clinical Pharmacology, 2004; 44:559–69.
14. Mare chal JD, Jinglei Yu, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GCK, Paine MJI, Sutcliffe MJ, In silico and invitro screening for inhibition of cytochrome p450 cyp3A4 by comedications commonly used by patients with cancer, Drug Metabolism and Disposition, 2006; 34(4): 534-538.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Draft Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Feb 2012.
16. Chen Y, Liu L, Laille E, Kumar G, Surapaneni S, In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine, Cancer Chemotherapy and Pharmacology, 2010; 65:995-1000.
17. Seervi M, Lotankar S, Barbar S, Sathaye S, Assessment of cytochrome P450 inhibition and induction potential of lupeol and betulin in rat liver microsomes, Drug Metabolism and Personalized Therapy, 2016; aop.
18. David M, Stresser Strategies for In VitroCYP Inhibition Testing and Alignment with FDA Guidance.
19. Wang JJ, Guo JJ, Zhan J, Bu HZ, H, Lin JH, An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes, Journal of PharmaceuticalAnalysis, 2014; 4(4):270–278.
20. Jeong S, Nguyen PD, Desta Z, Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A, Antimicrobial agents and chemotherapy, 2009; 53(2):541–551.
21. Obach RS, The importance of nonspecific binding in invitro matrices, its impact on enzymekinetic studies of drug metabolism reactions, and implications for invitro-invivo correlations, Drug Metabolism and Disposition,1996; 24:1047–1049.
22. Tran TH, Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ, Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A4 inhibitors, Drug Metabolism and Disposition, 2002; 30:1441-1445.
23. Busby WF Jr, Ackermann JM, Crespi CL, Effect of methanol, ethanol, dimethylsulfoxide, and acetonitrile on invitro activities of cDNA-expressed human cytochromesP-450, Drug Metabolism and Disposition, 1999; 27: 246–249.
24. Chauret N, Gauthier A, Nicoll-Griffith DA, Effect of common organic solvents on invitro cytochrome P450-mediated metabolic activities in human liver microsomes, Drug Metabolism and Disposition, 1998; 26:1–4.
25. Ramasamy S, Kiew LV, Chung LY, Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents, Molecules, 2014; 19:2588–601.
26. Martignoni M, Groothuis GM, De KR, Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction, Expert Opinion on Drug Metabolism & Toxicology, 2006; 2:875–94.
27. Bailey DG, Malcolm J, Arnold O, Spence JD, Grapefruit juice drug interactions, British Journal of Clinical Pharmacology, 1998; 46:101–10.
28. Ho BE,, Shen DD, McCune JS, Bui T, Risler L, Yang Z, Ho RJ, Effects of garlic on cytochromes P450 2C9 and 3A4 mediated drug metabolism in human hepatocytes, Scientia Pharmaceutica, 2010; 78:473–81.
29. Dae Hun Suh, Seoul National University Hospital, Clinical Trial of Lupeol for Mild-moderate Acne, ClinicalTrials.gov. 2014; NCT02152865.
30. Dae Hun Suh, Seoul National University Hospital, Clinical Study for Topical Lupeol in Acne ClinicalTrials.gov. 2014; NCT02205892.
31. Wal A, Srivastava RS, Wal P, Rai A, Sharma S, Lupeol as a magical drug, Pharmaceutical and Biological Evaluations, 2015; 2(5):142-151.
Statistics
279 Views | 284 Downloads
How to Cite
1.
KHATAL L, More H. In-vitro assessment of CYP3A4 and CYPC29 inhibition potential of Lupeol using human liver microsomes. JDDT [Internet]. 15Mar.2019 [cited 24Oct.2021];9(2):231-6. Available from: http://www.jddtonline.info/index.php/jddt/article/view/2562